서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Title

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 5,116 to 5,135 of 7,543

Issue DateTitle / Author(s) / CitationFileAltmetrics
2020-08
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
DOI
2018-01
S-1-induced lacrimal drainage obstruction and its association with ingredients/metabolites of S-1 in tears and plasma: A prospective multi-institutional study
DOI
2017-02
S100A8 and S100A9 induction is involved in inflammation-associated hepatocarcinogenesis under hypoxic conditions via the JNK pathway
view file
2017-08
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
DOI
2018-01
Safety and antitumor activity of pembrolizumab in advanced programmed death Ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study
DOI
2018-06
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
DOI
2021-12
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
DOI
2021-03
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
DOI
2022-10
Safety and efficacy of clonazepam in patients with hemifacial spasm: A double-blind, randomized, placebo-controlled trial
DOI
2014-10
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
DOI
2020-02
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DOI
2021-07
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
DOI
2022-11
Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment: A phase I randomized controlled trial
DOI
2020-06
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
DOI
2022-06
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
DOI
2018-05
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
DOI
2022-11
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
DOI
2021-03
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
2020-12
Safety and feasibility of robotic major hepatectomy for novice surgeons in robotic liver surgery: A prospective multicenter pilot study
DOI
2021-08
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
DOI
1255 256 257 258 259 260 261378